HyperCVAD plus Imatinib or Dasatinib in Lymphoid Blastic Phase Chronic Myeloid Leukemia

BACKGROUND: Chronic Myeloid Leukemia (CML) may progress to blast phase (BP) at the rate of 1–1.5% per year. With the use of single-agent tyrosine kinase inhibitors (TKI), median overall survival (OS) ranges between 7 and 11 months. METHODS: We analyzed the outcome of 42 patients with lymphoid BP-CML...

Full description

Saved in:
Bibliographic Details
Main Authors: Strati, Paolo, Kantarjian, Hagop, Thomas, Deborah, O’Brien, Susan, Konoplev, Sergej, Jorgensen, Jeffrey L, Luthra, Raja, Abruzzo, Lynne, Jabbour, Elias, Quintas-Cardama, Alfonso, Borthakur, Gautam, Faderl, Stefan, Ravandi, Farhad, Cortes, Jorge
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946911/
https://ncbi.nlm.nih.gov/pubmed/24151050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28433
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items